Polyethylene glycol interferon-alpha 2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia


Por: Cervantes F, Camós-Guijosa M, Boqué C, Besses C, Alcalá A and Sureda A

Publicada: 1 jul 2004
Categoría: Hematology

Resumen:
Thirty-five patients newly diagnosed with chronic myeloid leukemia received pegylated interferon alpha-2b (PEG-IFN) alone or combined with intermittent Ara-C for a median of 6.5 months (range: 1.4-19.2). The median weekly PEG-IFN dose was 4.0 microg/kg. Complete hematologic, major and complete cytogenetic responses were observed in 73%, 32% and 14%, respectively. Extra-hematologic side-effects were frequent and 20% of patients had grade III-IV hematologic toxicity.
ISSN: 03906078





HAEMATOLOGICA
Editorial
FERRATA STORTI FOUNDATION, VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY, Italia
Tipo de documento: Letter
Volumen: 89 Número: 7
Páginas: 870-871
WOS Id: 000222650200018
ID de PubMed: 15257944

MÉTRICAS